Back

ARNi treatment in adults with Tetralogy of Fallot: a single-centre experience

13 May 2024 (15:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Andre Paulo Ferreira

Hospital de Santa Marta, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
The impact of modifiable risk factors on readmissions during the vulnerable period in patients with heart failure
Assistant Professor A. Lacraru (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study
Professor M. Ufnal (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Effect of intravenous FCM therapy on myocardial work indices in patients with HFrEF and ID.
Professor A. Safarova (Baku, AZ)
Abstract Slides Video
Presentation thumbnail
Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance
Professor J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effect of guideline-recommended medical therapy according to blood urea nitrogen
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

13 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan reverse remodelling in adults with univentricular hearts or systemic right ventricles
thumbnail
Congress Presentation
Short-term effects on sacubitril/valsartan therapy on right ventricle work and mechanics in patients with heart failure and reduced ejection fraction
thumbnail
Congress Presentation
The anti-remodeling effect of sacubitril/valsartan in myocardial samples of end-stage heart failure patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources